Preview

«Парадокс ожирения» – еще один взгляд на проблему сердечно-сосудистых заболеваний

https://doi.org/10.14341/omet201343-9

Полный текст:

Аннотация

Крупные эпидемиологические исследования прошлого века продемонстрировали, что последствием ожирения являются такие тяжелые заболевания, как сахарный диабет, артериальная гипертония, ишемическая болезнь сердца, хроническая сердечная недостаточность, нарушения мозгового кровообращения. В развитых странах сердечно-сосудистые заболевания стали лидирующей причиной смертности. За последние 5–6 лет появились сведения о том, что люди с избыточной массой тела и ожирением I степени имеют более высокую продолжительность жизни, чем лица с нормальным весом. В 2009 году опубликованы данные о том, у пациентов с хронической сердечной недостаточности наличие ожирения не ухудшает сердечно-сосудистый прогноз: избыточная масса тела коррелирует с уменьшением общей смертности на 25%, а при ожирении I степени риск смерти снижается на 12%. Этот феномен получил название «парадокса ожирения», причины которого рассмотрены в данном обзоре.

Об авторах

O V Shpagina



I Z Bondarenko

д.м.н, гл.н.с. отделения кардиологии


Список литературы

1. AACE Medical Guidelines for clinical practice for growth hormone use in growth hormone – deficient adults and transition patients, 2009. Update ENDOCRINE PRACTICE. 2009; 15 September/October 1.

2. Angeras O., Albertsson P., Karason K. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J. 2013 Feb; 34(5): 345–53.

3. Calle E., Thun M., Petrelli J. Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults N Engl J Med. 1999; 341: 1097–1105.

4. Carmichael J.D., Danoff A., Milani D. GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50–90. Clin Endocrinol (Oxf). 2006; 65(2): 169–77.

5. Carrillo A., Rising R., Tverskaya R. Effects of Exogenous Recombinant Human Growth Hormone on an Animal Model of Suboptimal Nutrition. J Am Coll Nutr. June 1998; 17 (3): 276–281.

6. Сlinicaltrials.gov/. http://clinicaltrials.gov/ct2/show/NCT01438086?term=RESUS+AMI&rank=1.

7. Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol. 1992; 37: 387–397.

8. Degoulet P, Legrain M, Réach I. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. 1982; 31(2): 103–10.

9. Dessi-Fulgheri P, Sarzani R, Serenelli M. Low calorie diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives. Hypertension. 1999; 33: 658–62.

10. Dorner TE, Rieder A. Obesity paradox in elderly patients with cardiovascular diseases. 2012 Feb 23; 155(1): 56–65.

11. Dudina A, Cooney MT, Bacquer DD. Relationships between body mass index, cardiovascular mortality, and risk factors: a report from the SCORE investigators. Eur J Cardiovasc Prev Rehabil. 2011; Oct 18(5): 731–42.

12. Feldman AM, Combes A, Wagner D. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000 Mar 1; 35 (3): 537–44.

13. Fleischmann E, Teal N, Dudley J. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int. 1999 Apr; 55(4): 1560–7.

14. Fonarow GC, Srikanthan P, Costanzo MR. An obesity paradox in acute heart failure: analysis of body mass index and in hospital mortality for 108,927 patients in the Acute Decompensated Heart Failure. National Registry. 2007; 153(1): 74–81.

15. Habbu A., Lakkis N., Dokainish H. The Obesity Paradox: Fact or Fiction? Am J Cardiol. 2006; 98 (7): 944–948.

16. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system; Am J Hypertens. 2001 Jun; 14 (6 Pt 2): 103S–115S.

17. Hassani SE, Chu WW, Wolfram RM. Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. 2006.

18. Hastie CE, Padmanabhan S, Slack R. Obesity paradox in a cohort of 4,880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J. 2010 Jan; 31(2): 222–6.

19. Hong NS, Kim KS, Lee IK. The association between obesity and mortality in the elderly differs by serum concentrations of persistent organic pollutants: a possible explanation for the obesity paradox. Int J Obes (Lond). 2012 Sep; 36(9): 1170–5.

20. Iranmanesh A, Lizarrade G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in health men. J Clin Endocrinol Metab. 1991; 73(5): 1081–1088.

21. Ittermann T, Noord C, Friedrich N. The association between insulin-like growth factor-I and cardiac repolarization. Growth Hormone & IGF Research. 2012; 22 (1): 1–5.

22. Janssen J, Lamberts S. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol. 2002; 146 (4): 467–477.

23. Janssen J, Stolk R, Pols H. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vase Biol. 1998; 18: 277–282.

24. Kalantar-Zadeh K, Block G, Horwich T. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004; 43: 1439–44.

25. Kern Ph., Ranganathan S., Li Ch., Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol. 2001; 280 E: 745–751.

26. Lavie CJ, De Schutter A, Patel DA. Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the "obesity paradox". 2012 Oct 9; 60(15): 1374–80.

27. Lavie CJ, Mehra MR, Milani RV. Obesity and heart failure prognosis: paradox or reverse epidemiology. Eur Heart J. 2005; 26: 5–7.

28. Lavie CJ, Milani RV, Ventura HO. Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am J Cardiol. 2007; 100: 1460–4.

29. Lin SX, Pi-Sunyer EX. Prevalence of the metabolic syndrome among US middle-aged and older adults with and without diabetes – a preliminary analysis of the NHANES 1999–2002 data. Ethn Dis. 2007; 17(1): 35–9.

30. Longenecker CT, Dunn W, Jiang Y. Adipokines and vascular health in treated HIV infection: an obesity paradox? AIDS. 2013 Mar 4. [Epub ahead of print].

31. Lundberg G.D. Is there a relationship between waist circumference and mortality? 2008; 10(8): 202. Epub 2008 Aug 28.

32. Maeda N., Takahashi M., Funahashi T. PPAR-ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes. 2001; 50: 2094–2099.

33. Makimura H, Stanley T, Mun D. Reduced Growth Hormone Secretion Is Associated with Increased Carotid Intima-Media Thickness in Obesity. J Clin Endocrinol Metab. 2009 December; 94(12): 5131–5138.

34. McNeill AM, Rosamond WD, Girman CJ. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities (ARIC) study. Diabetes care. 2005; 28(2): 385–90 Feb.

35. Niebauer J, Volk HD, Kemp M. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999 May 29; 353(9167): 1838–42.

36. Oreopoulos A, McAlister FA, Kalantar-Zadeh K. The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH. Eur Heart J. 2009; 30: 2584–92.

37. Oreopoulos A, Padwal R, Kalantar-Zadeh K. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008; 156(1): 13–22.

38. Pocock S.J., McMurray J.J., Dobson J. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008 Nov; 29(21): 2641–50.

39. Rajamanickam A., Kapadia S., Butler S. Does “The Obesity Paradox” exist for survival after a Percutaneous intervention? J Am Coll Cardiol. 2010; 55, Issue 10s1.

40. Rajpathak S, Gunter M, Wylie-Rosett J. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev. 2009; 25 (1): 3–12.

41. Rasmussen M., Hvidberg A., Juul, A. “Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects,” The Journal of Clinical Endocrinology & Metabolism. 1995; 80 (4): 1407–1415.

42. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol. 1999; 31: 2049–2061.

43. Romero-Corral A, Montori VM, Somers VK. Association of Body weight with total mortality and with cardiovascular events in Coronary artery disease: a systematic review of cohort studies. Lancet 2006; 368: 666–78.

44. Sattar, N., G. Wannamethee, N. Sarwar, J. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. 2006; 114(7): 623–9.

45. Schneider HJ, Klotsche J, Saller B. Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients. European Journal of Endocrinology. 2008; 158: 153–161.

46. Shibata R., Izumiya Y., Sato K. “Adiponectin protects against the development of systolic dysfunction following myocardial infarction”, Journal of Molecular and Cellular Cardiology. 2007; 42 (6): 1065–1074.

47. Shibata R., Ouchi N., Ito M. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nature Medicine. 2004; 10 (12): 1384–1389.

48. Sorkin JD, Muller DC, Andres R. Longitudinal change in height of men and women: implications for interpretation of the body mass index: the Baltimore Longitudinal Study of Aging. Am J Epidemiol. 1999; 150: 969–77.

49. Stamler R, Ford CE, Stamler J. Why do lean hypertensive patients have higher mortality rates than other hypertensive patients? Findings of the hypertension detection and follow-up program. Hypertension. 1991; 17: 553–64.

50. Tao L., Gao E., Jiao X. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 2007; 115(11): 1408–16.

51. The WHO MONICA Project 1980–1990. http://www.thl.fi/publications/monica/index.html.

52. Trayhurn P., Wood I. S. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochemical Society Transactions. 2005; 33: 1078–1081.

53. Tuomilehto J. Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. Am J Med 1991; 90: 34S–41S.

54. Uretsky S, Messerli FH, Bangalore S. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007; 120: 863–70.

55. Van den Beld A, Bots M, Janssen J. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003; 157: 25–31.

56. Von Eynatten M., Hamann A., Twardella D. Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J. 2008; 29(10): 1307–15.

57. Wallace A.M., McMahon A.D., Packard C.J. et al. Plasma leptin and the risk of cardiovascular disease in the West Of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001; 104: 3052–3056.

58. Wallerstedt S.M., Eriksson A.L., Niklason A. et al. Serum leptin and myocardial infarction in hypertension. Blood Press. 2004; 13: 243–246.

59. WHO Report «Burdens of Disease», 2008. http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html


Для цитирования:


Shpagina O.V., Bondarenko I.Z. «Парадокс ожирения» – еще один взгляд на проблему сердечно-сосудистых заболеваний. Ожирение и метаболизм. 2013;10(4):3-9. https://doi.org/10.14341/omet201343-9

For citation:


., . Obesity Paradox" – another look at the problem of cardiovascular disease. Obesity and metabolism. 2013;10(4):3-9. (In Russ.) https://doi.org/10.14341/omet201343-9

Просмотров: 33


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)